This page shows the latest acute myeloid leukemia news and features for those working in and with pharma, biotech and healthcare.
The FLT3 inhibitor received the positive opinion for use as a monotherapy in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. ... 2017. AML is the most common form of acute leukaemia in adults and has a low
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic
AbbVie and Roche believe that venetoclax will be effective across a range of blood cancers, and are testing the drug in acute myeloid leukemia, non-Hodgkin's lymphoma, and multiple myeloma
The National Institute for Health and Care Excellence (NICE) has turned down Celgene's Vidaza to treat older people with acute myeloid leukemia (AML) in final draft guidance.
First EU-wide licence for the acute lymphoblastic leukaemia treatment. Baxalta's aspirations in oncology have received a boost after the European Commission approved Oncaspar, its treatment for a rare form ... Baxalta also plans to investigate Oncaspar
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. ... Some of the world's leading experts in the treatment of acute lymphoblastic leukaemia (ALL) and acute myeloid
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Valid Insight is an award-winning pharmaceutical global market access consultancy....